Dopamine and antipsychotic drug action revisited

The key event in the initiation of pharmacological responses is the formation of a complex between the ligand (or drug or molecule) and its site of action ([Taylor & Insel, 1990][1]). Competitive binding experiments ascertain how specific the interaction is between a ligand and its binding site by

[1]  C. Halldin,et al.  No support for regional selectivity in clozapine-treated patients: a PET study with [(11)C]raclopride and [(11)C]FLB 457. , 2001, The American journal of psychiatry.

[2]  K. Erlandsson,et al.  Optimizing Limbic Selective D2/D3 Receptor Occupancy by Risperidone: A [123I]-Epidepride SPET Study , 2003, Journal of clinical psychopharmacology.

[3]  P. Goldman-Rakic,et al.  The cerebral cortex: a case for a common site of action of antipsychotics. , 1998, Trends in pharmacological sciences.

[4]  M. Travis,et al.  In vivo 5-HT2A receptor blockade by quetiapine , 2001, Psychopharmacology.

[5]  C. Marsden,et al.  Changes in rat striatal dopamine turnover and receptor activity during one years neuroleptic administration. , 1980, European journal of pharmacology.

[6]  R. Kerwin,et al.  5-HT2A receptor blockade in patients with schizophrenia treated with risperidone or clozapine , 1998, British Journal of Psychiatry.

[7]  S. Heckers,et al.  Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia , 2001, Biological Psychiatry.

[8]  P. Seeman,et al.  Antipsychotic drug doses and neuroleptic/dopamine receptors , 1976, Nature.

[9]  P. Strange,et al.  Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects. , 2001, Pharmacological reviews.

[10]  R. Murray,et al.  Antipsychotic medication, D2 dopamine receptor blockade and clinical response: a 123I IBZM SPET (single photon emission tomography) study , 1993, Psychological Medicine.

[11]  H. Meltzer,et al.  The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. , 1989, Psychopharmacology bulletin.

[12]  S. Kapur,et al.  Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. , 2000, The American journal of psychiatry.

[13]  S. Kapur,et al.  Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. , 2001, The American journal of psychiatry.

[14]  K. Melkersson,et al.  Dose requirement and prolactin elevation of antipsychotics in male and female patients with schizophrenia or related psychoses. , 2001, British journal of clinical pharmacology.

[15]  D. Visvikis,et al.  In vivo occupancy of striatal and temporal cortical D2/D3 dopamine receptors by typical antipsychotic drugs , 1999, British Journal of Psychiatry.

[16]  S. Marder,et al.  Low-dose treatment strategies. , 1986, The Journal of clinical psychiatry.

[17]  A. Malhotra,et al.  Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[18]  C. Thompson.  The Use of High-Dose Antipsychotic Medication , 1994, British Journal of Psychiatry.

[19]  S. Kapur,et al.  Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. , 1999, The American journal of psychiatry.

[20]  S. Kapur,et al.  A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. , 2000, Archives of general psychiatry.

[21]  R. Baldessarini,et al.  Dissimilar dosing with high-potency and low-potency neuroleptics. , 1984, The American journal of psychiatry.

[22]  J. Baron,et al.  Striatal D2 dopaminergic receptors assessed with positron emission tomography and [76Br]bromospiperone in untreated schizophrenic patients. , 1990, The American journal of psychiatry.

[23]  G. Sedvall,et al.  D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics , 2004, Psychopharmacology.

[24]  R. Murray,et al.  D2 Dopamine Receptor Binding in the Basal Ganglia of Antipsychotic-Free Schizophrenic Patients , 1994, British Journal of Psychiatry.

[25]  J. Krystal,et al.  Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[26]  A. Kouchi,et al.  Mixing basaltic and dacitic magmas by forced convection , 1983, Nature.

[27]  T. Crow,et al.  MECHANISM OF THE ANTIPSYCHOTIC EFFECT IN THE TREATMENT OF ACUTE SCHIZOPHRENIA , 1978, The Lancet.

[28]  G. Reynolds.  Increased concentrations and lateral asymmetry of amygdala dopamine in schizophrenia , 1983, Nature.

[29]  P. Seeman,et al.  Elevation of brain neuroleptic/dopamine receptors in schizophrenia. , 1980, The American journal of psychiatry.

[30]  J. Hagan,et al.  Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A. , 2000, The Journal of pharmacology and experimental therapeutics.

[31]  S. Snyder,et al.  Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. , 1976, Science.

[32]  R. Kessler,et al.  Cognition, schizophrenia, and the atypical antipsychotic drugs. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[33]  S. Stone-Elander,et al.  D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride. , 1990, Archives of general psychiatry.

[34]  Christer Halldin,et al.  Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: A double-blind PET study of schizophrenic patients , 1993, Biological Psychiatry.

[35]  Holly Moore,et al.  The regulation of forebrain dopamine transmission: relevance to the pathophysiology and psychopathology of schizophrenia , 1999, Biological Psychiatry.

[36]  L L Iversen,et al.  Increased brain dopamine and dopamine receptors in schizophrenia. , 1982, Archives of general psychiatry.

[37]  A. Goldstein,et al.  Principles of Drug Action. The Basis of Pharmacology , 1970 .

[38]  S. Peroutka,et al.  Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic, and histamine receptors to clinical potency. , 1980, The American journal of psychiatry.

[39]  M. Bergström,et al.  Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel®) in patients with schizophrenia , 1998, Psychopharmacology.

[40]  Peter J Ell,et al.  Limbic selectivity of clozapine , 1997, The Lancet.

[41]  T. Cooper,et al.  Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. , 1989, The American journal of psychiatry.

[42]  R. Kerwin,et al.  Striatal and extra-striatal D(2)/D(3) dopamine receptor occupancy by quetiapine in vivo. [(123)I]-epidepride single photon emission tomography(SPET) study. , 2000, The British journal of psychiatry : the journal of mental science.

[43]  R. Kerwin.  The New Atypical Antipsychotics , 1994, British Journal of Psychiatry.

[44]  R. M. Murray,et al.  Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia , 1992, The Lancet.

[45]  L. Mallet,et al.  Extrastriatal and striatal D2 dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia , 2001, British Journal of Psychiatry.